Financhill
Sell
35

TCRT Quote, Financials, Valuation and Earnings

Last price:
$1.65
Seasonality move :
1.77%
Day range:
$1.65 - $1.74
52-week range:
$1.50 - $26.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.98x
Volume:
7.5K
Avg. volume:
26K
1-year change:
-92.16%
Market cap:
$2.7M
Revenue:
$5K
EPS (TTM):
-$7.41

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Upside
    No price target exists because of limited analyst coverage.
  • Price Target Downside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, Alaunos Therapeutics has 12205.38% upside to fair value with a price target of -- per share.

TCRT vs. S&P 500

  • Over the past 5 trading days, Alaunos Therapeutics has overperformed the S&P 500 by 3.86% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Alaunos Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Alaunos Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Alaunos Therapeutics reported revenues of $4K.

Earnings Growth

  • Alaunos Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Alaunos Therapeutics reported earnings per share of -$0.70.
Enterprise value:
991.2K
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.08x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-144.17%
Net Income Margin (TTM):
--
Return On Equity:
-189.69%
Return On Invested Capital:
-189.69%
Operating Margin:
-29150%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -$37M -$33.7M -$7.4M -$7.2M -$1.2M
EBITDA -$34.6M -$30.9M -$11.5M -$7.8M -$1.1M
Diluted EPS -$28.50 -$23.09 -$7.41 -$5.30 -$0.70
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $155.1M $96.6M $55.5M $12.9M $3.6M
Total Assets $165.9M $113.8M $67.3M $19.4M $3.6M
Current Liabilities $19.3M $28.2M $32.9M $4.7M $826K
Total Liabilities $21M $45.1M $35.2M $5.5M $826K
Total Equity $144.9M $68.7M $32.1M $13.9M $2.7M
Total Debt -- $24.2M $22.7M -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$37.2M -$29.9M -$11.8M -$6.4M -$781K
Cash From Investing -$459K -$250K $1.5M $1K --
Cash From Financing -$2.3M -$9.7M -- -- --
Free Cash Flow -$37.7M -$30.2M -$11.8M -$6.4M -$781K
TCRT
Sector
Market Cap
$2.7M
$43.3M
Price % of 52-Week High
6.42%
47.98%
Dividend Yield
0%
0%
Shareholder Yield
19.63%
-0.75%
1-Year Price Total Return
-92.16%
-36.92%
Beta (5-Year)
-0.401
0.753
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $1.61
200-day SMA
Sell
Level $4.46
Bollinger Bands (100)
Sell
Level 1.71 - 2.63
Chaikin Money Flow
Sell
Level -259.9M
20-day SMA
Sell
Level $1.70
Relative Strength Index (RSI14)
Sell
Level 45.85
ADX Line
Buy
Level 10.83
Williams %R
Neutral
Level -69.6429
50-day SMA
Sell
Level $1.90
MACD (12, 26)
Sell
Level -0.08
25-day Aroon Oscillator
Sell
Level -28
On Balance Volume
Neutral
Level 65M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-162.2997)
Sell
CA Score (Annual)
Level (-4.0392)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (32.9886)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.

Stock Forecast FAQ

In the current month, TCRT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TCRT average analyst price target in the past 3 months is --.

  • Where Will Alaunos Therapeutics Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Alaunos Therapeutics share price will rise to -- per share over the next 12 months.

  • What Do Analysts Say About Alaunos Therapeutics?

    Analysts are divided on their view about Alaunos Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Alaunos Therapeutics is a Sell and believe this share price will drop from its current level to --.

  • What Is Alaunos Therapeutics's Price Target?

    The price target for Alaunos Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is TCRT A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Alaunos Therapeutics is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of TCRT?

    You can purchase shares of Alaunos Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Alaunos Therapeutics shares.

  • What Is The Alaunos Therapeutics Share Price Today?

    Alaunos Therapeutics was last trading at $1.65 per share. This represents the most recent stock quote for Alaunos Therapeutics. Yesterday, Alaunos Therapeutics closed at $1.67 per share.

  • How To Buy Alaunos Therapeutics Stock Online?

    In order to purchase Alaunos Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Will Palantir Stock Be Worth in 2030?
What Will Palantir Stock Be Worth in 2030?

Palantir Technologies (NYSE: PLTR) has emerged from a growth slowdown…

Is Rollins Stock a Buy, Sell or Hold?
Is Rollins Stock a Buy, Sell or Hold?

Pest control giant Rollins (NYSE:ROL) is the parent company of…

Why Did Bill Ackman Buy Uber?
Why Did Bill Ackman Buy Uber?

In early 2025, billionaire investor Bill Ackman, CEO of Pershing…

Stock Ideas

Buy
61
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 39x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 110x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Buy
58
UPST alert for Feb 13

Upstart Holdings [UPST] is up 31.82% over the past day.

Buy
79
CFLT alert for Feb 13

Confluent [CFLT] is up 24.92% over the past day.

Buy
52
BL alert for Feb 13

BlackLine [BL] is down 18.03% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock